TCWM
MRTX

Total Clarity Wealth Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Total Clarity Wealth Management’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-210
Closed -$27K – 665
2019
Q4 		$27K Buy
+210
New +$20.3K 0.02% 353

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Total Clarity Wealth Management's MRTX Position: Q1 2020 in Review

Total Clarity Wealth Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2020, closing a stake of 210 shares — an estimated $27K sold.

Total Clarity Wealth Management first reported a position in MRTX in Q4 2019 and held it in 1 quarter. The position peaked at $27K in Q4 2019. 173 funds tracked by Wall St. Rank hold MRTX as of Q1 2020.

  • Total Clarity Wealth Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
  • Total Clarity Wealth Management sold 210 Mirati Therapeutics, Inc. Common Stock shares in Q1 2020, an estimated $27K.
  • Total Clarity Wealth Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2019 and held it in 1 quarter.
  • Total Clarity Wealth Management's Mirati Therapeutics, Inc. Common Stock position peaked at $27K in Q4 2019.
  • 173 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2020.

Based on Total Clarity Wealth Management's 13F filing for Q1 2020, filed 24 Apr 2020.